46 related articles for article (PubMed ID: 9664139)
1. SUMOylation inhibition enhances dexamethasone sensitivity in multiple myeloma.
Du L; Liu W; Aldana-Masangkay G; Pozhitkov A; Pichiorri F; Chen Y; Rosen ST
J Exp Clin Cancer Res; 2022 Jan; 41(1):8. PubMed ID: 34983615
[TBL] [Abstract][Full Text] [Related]
2. A novel alkylating agent Melflufen induces irreversible DNA damage and cytotoxicity in multiple myeloma cells.
Ray A; Ravillah D; Das DS; Song Y; Nordström E; Gullbo J; Richardson PG; Chauhan D; Anderson KC
Br J Haematol; 2016 Aug; 174(3):397-409. PubMed ID: 27098276
[TBL] [Abstract][Full Text] [Related]
3. Modulation of cell metabolic pathways and oxidative stress signaling contribute to acquired melphalan resistance in multiple myeloma cells.
Zub KA; Sousa MM; Sarno A; Sharma A; Demirovic A; Rao S; Young C; Aas PA; Ericsson I; Sundan A; Jensen ON; Slupphaug G
PLoS One; 2015; 10(3):e0119857. PubMed ID: 25769101
[TBL] [Abstract][Full Text] [Related]
4. ABL1 kinase plays an important role in spontaneous and chemotherapy-induced genomic instability in multiple myeloma.
Kumar S; Talluri S; Zhao J; Liao C; Potluri LB; Buon L; Mu S; Shi J; Chakraborty C; Tai YT; Samur MK; Munshi NC; Shammas MA
Blood; 2024 Mar; 143(11):996-1005. PubMed ID: 37992230
[TBL] [Abstract][Full Text] [Related]
5. Multiple myeloma with t(11;14): impact of novel agents on outcome.
Puertas B; González-Calle V; Sobejano-Fuertes E; Escalante F; Rey-Bua B; Padilla I; García-Sanz R; Puig N; Gutiérrez NC; Mateos MV
Blood Cancer J; 2023 Mar; 13(1):40. PubMed ID: 36935422
[TBL] [Abstract][Full Text] [Related]
6. Looking into Endoplasmic Reticulum Stress: The Key to Drug-Resistance of Multiple Myeloma?
Wang G; Fan F; Sun C; Hu Y
Cancers (Basel); 2022 Oct; 14(21):. PubMed ID: 36358759
[TBL] [Abstract][Full Text] [Related]
7. Clinical Review: Navitoclax as a Pro-Apoptotic and Anti-Fibrotic Agent.
Mohamad Anuar NN; Nor Hisam NS; Liew SL; Ugusman A
Front Pharmacol; 2020; 11():564108. PubMed ID: 33381025
[TBL] [Abstract][Full Text] [Related]
8. Dihydroartemisinin Induces Growth Arrest and Overcomes Dexamethasone Resistance in Multiple Myeloma.
Chen Y; Li R; Zhu Y; Zhong S; Qian J; Yang D; Jurczyszyn A; Beksac M; Gu C; Yang Y
Front Oncol; 2020; 10():767. PubMed ID: 32500030
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone Inhibits Spheroid Formation of Thyroid Cancer Cells Exposed to Simulated Microgravity.
Melnik D; Sahana J; Corydon TJ; Kopp S; Nassef MZ; Wehland M; Infanger M; Grimm D; Krüger M
Cells; 2020 Feb; 9(2):. PubMed ID: 32033410
[TBL] [Abstract][Full Text] [Related]
10. Aspirin enhances the cytotoxic activity of bortezomib against myeloma cells via suppression of Bcl-2, survivin and phosphorylation of AKT.
Ding JH; Yuan LY; Chen GA
Oncol Lett; 2017 Feb; 13(2):647-654. PubMed ID: 28356941
[TBL] [Abstract][Full Text] [Related]
11. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenström macroglobulinaemia.
Paulus A; Chitta K; Akhtar S; Personett D; Miller KC; Thompson KJ; Carr J; Kumar S; Roy V; Ansell SM; Mikhael JR; Dispenzieri A; Reeder CB; Rivera CE; Foran J; Chanan-Khan A
Br J Haematol; 2014 Feb; 164(3):352-365. PubMed ID: 24236538
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-6 and JAK2/STAT3 signaling mediate the reversion of dexamethasone resistance after dexamethasone withdrawal in 7TD1 multiple myeloma cells.
Liu T; Fei Z; Gangavarapu KJ; Agbenowu S; Bhushan A; Lai JC; Daniels CK; Cao S
Leuk Res; 2013 Oct; 37(10):1322-8. PubMed ID: 23871159
[TBL] [Abstract][Full Text] [Related]
13. Potential therapeutic benefits of strategies directed to mitochondria.
Camara AK; Lesnefsky EJ; Stowe DF
Antioxid Redox Signal; 2010 Aug; 13(3):279-347. PubMed ID: 20001744
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid exerts anti-tumor as well as anti-angiogenic effects on myeloma.
Kitazoe KI; Abe M; Hiasa M; Oda A; Amou H; Harada T; Nakano A; Takeuchi K; Hashimoto T; Ozaki S; Matsumoto T
Int J Hematol; 2009 Jan; 89(1):45-57. PubMed ID: 19093163
[TBL] [Abstract][Full Text] [Related]
15. Plant programmed cell death: can't live with it; can't live without it.
Williams B; Dickman M
Mol Plant Pathol; 2008 Jul; 9(4):531-44. PubMed ID: 18705866
[TBL] [Abstract][Full Text] [Related]
16. Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM).
Chauhan D; Neri P; Velankar M; Podar K; Hideshima T; Fulciniti M; Tassone P; Raje N; Mitsiades C; Mitsiades N; Richardson P; Zawel L; Tran M; Munshi N; Anderson KC
Blood; 2007 Feb; 109(3):1220-7. PubMed ID: 17032924
[TBL] [Abstract][Full Text] [Related]
17. BAFF and APRIL protect myeloma cells from apoptosis induced by interleukin 6 deprivation and dexamethasone.
Moreaux J; Legouffe E; Jourdan E; Quittet P; Rème T; Lugagne C; Moine P; Rossi JF; Klein B; Tarte K
Blood; 2004 Apr; 103(8):3148-57. PubMed ID: 15070697
[TBL] [Abstract][Full Text] [Related]
18. Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma.
Chen Q; Ray S; Hussein MA; Srkalovic G; Almasan A
Leuk Lymphoma; 2003 Jul; 44(7):1209-14. PubMed ID: 12916874
[TBL] [Abstract][Full Text] [Related]
19. Bcl-2 overexpression is associated with resistance to dexamethasone, but not melphalan, in multiple myeloma cells.
Gazitt Y; Fey V; Thomas C; Alvarez R
Int J Oncol; 1998 Aug; 13(2):397-405. PubMed ID: 9664139
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
